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Atrial Fibrillation and Myocardial Infarction: A Systematic Review and
Appraisal of Pathophysiologic Mechanisms
Francesco Violi, MD; Elsayed Z. Soliman, MD; Pasquale Pignatelli, MD; Daniele Pastori, MD
Background-—A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI).
However, incidence and management of MI in AF is still undefined.
Methods and Results-—We searched MEDLINE via PubMed and Cochrane database between 1965 and 2015. All observational
clinical studies and interventional trials reporting 1-year incidence of MI in AF were included. We also discussed
pathophysiological mechanisms, predictors, and therapeutic approaches to reduce the risk of MI in AF. Twenty-one observational
studies and 10 clinical trials were included. The annual rate of MI in observational studies including AF patients ranged from 0.4%
to 2.5%. Higher rates of MI were reported in AF patients with stable coronary artery disease (11.5%/year), vascular disease
(4.47%/year), heart failure (2.9%/year), and in those undergoing coronary artery interventions (6.3%/year). However, lower annual
rates have been described in AF patients from Eastern countries (0.2–0.3%/year), and in those enrolled in clinical trials (from 0.4
to 1.3%/year).
Conclusions-—AF patients had a significant residual risk of MI despite anticoagulant treatment. Coexistence of atherosclerotic risk
factors and platelet activation account for the increased risk of MI in AF. Identification of high-risk AF patients is a needed first step
to develop cost-effective approaches for prevention. A new score, the 2MACE score, has been recently developed to stratify MI risk
in AF, and may help not only in allocating resources to high-risk groups, but also in design of studies examining novel therapies for
prevention of MI in AF. ( J Am Heart Assoc. 2016;5:e003347 doi: 10.1161/JAHA.116.003347)
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A trial fibrillation (AF) is the most frequent sustainedcardiac arrhythmia encountered in Western countries,
with millions of individuals expected to suffer from it in the
next decades. Progressive increase in the life expectancy is
the major drive for the high prevalence of AF in Western
countries.1 Aging has a negative impact not only for the
occurrence of AF but also for ischemic stroke, which sharply
increases in the elderly population as well.1 Consequently, the
clinical history of most AF patients is often complicated by
thromboembolic events; for this reason AF patients are treated
with oral anticoagulants such as vitamin K antagonists (VKAs) to
prevent the risk of ischemic stroke.2 In the last decade a new
anticoagulant category, non–vitamin K oral anticoagulants
(NOACs), has been introduced in the market. This includes a
direct thrombin inhibitor such as dabigatran, and factor Xa
inhibitors, namely, rivaroxaban, apixaban, and edoxaban.
Warfarin and NOACs are equivalent in terms of cerebrovascular
events reduction, but NOACs have been associated with less
risk of bleeding.3
In addition to thromboembolism, AF is characterized by a
constellation of atherosclerotic risk factors including hyper-
tension, diabetes, metabolic syndrome, and dyslipidemia and
by systemic signs of atherosclerosis such as aortic plaque or
peripheral artery disease, which can increase the risk of
stroke. It is for this reason that vascular disease has been
included in the new score for stroke risk stratification, ie, the
CHA2DS2-VASc score.
The association between systemic atherosclerosis and AF
can explain, at least partially, the complex clinical picture
complicating the disease course in AF patients. Thus,
atherosclerosis of coronary arteries with ensuing develop-
ment of acute coronary syndromes, such as myocardial
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infarction (MI), is another typical feature of AF clinical history.
Epidemiologic studies on the occurrence of MI provided
divergent results4–24; also unclear are the clinical and labora-
tory predictors, which may help to identify AF patients at high
risk of MI. The occurrence of MI in AF patients yields serious
problems of management. For example, the coexistence of
major adverse cardiovascular events (MACE) and thromboem-
bolism could require amore complex antithrombotic treatment.
This systematic review will focus on incidence of MI in
clinical trials and in observational studies, mechanisms of
disease, predictors of MI, and potential therapeutic
approaches to reduce the risk MI in AF.
Methods
Eligibility Criteria
We included all original clinical research articles in English
language with full text available. In particular, observational
clinical studies and interventional trials that reported data on
the incidence of MI in nonvalvular AF patients, with at least
1 year of follow-up and with no limitations regarding the type
of antithrombotic treatment, were selected. We did not
include the following: (1) case reports, editorials/comments,
letters; (2) subgroup analysis from the same clinical trial; (3)
studies reporting only cerebrovascular events as primary
outcome, and/or combined end point of ischemic events, or
other cardiovascular outcomes than MI (ie, mortality or
incident heart failure); and (4) studies investigating postacute
MI/cardiac revascularization AF.
Information Sources and Search Strategy
We performed a systematic review of the literature searching
MEDLINE via PubMed and Cochrane database for a combi-
nation of the following keywords: “atrial fibrillation,” “my-
ocardial infarction,” and “cardiovascular events.” The research
strategy included only journal articles in English language
between 1965 and 2015, and was performed according to
PRISMA guidelines.25
Study Selection
The study selection was performed in multiple phases. In the
first phase, potentially relevant studies were obtained by
combined searches of electronic databases using the selected
above-mentioned keywords. Then, studies not in English
language, with no abstract/full text available or not involving
humans, were excluded. In the second phase, studies were
reviewed and excluded by study typology; thus, letters,
editorials, case reports, and comments were excluded. The
third phase consisted of a detailed analysis of full-text articles
to assess whether they addressed the specific study question
(Figure 1).
Data Collection Process and Data Items
Two physicians (D.P., P.P.) independently screened the titles
and abstracts of manuscripts identified through the database
searches to identify studies potentially eligible for further
assessment. Controversies were resolved by a third investi-
gator (F.V.).
For each study we collected the following information:
authors, year of publication, study typology, antithrombotic
treatment, number of participants included, percentage of
women, age, CHADS2/CHA2DS2-VASc scores, follow-up
(year), number (n/%), and rate of MI (%/year).
Ethical Review
Given the study type (review article), an ethical approval was
not necessary.
Results
Study Selection
Our systematic review of literature yielded 3903 results
(Figure 1). Two-thousand ninety-one records were excluded
as 642 were not in English language, 842 had no abstract/
full text available, 356 were not involving humans, and 251
because they did not report keywords either in the title or
the abstract. Moreover, 40 were excluded by study typology
(letters/editorials/comments/case reports). Of the 1772
remaining full-text articles, 1175 did not include patients
with AF, and 508 included AF patients but did not address
the specific study question. Thus, 89 were eligible studies;
of these, we excluded 25 subgroup analysis of randomized
clinical trials, 25 studies reporting only composite end
point/other outcomes than MI, and 8 with a follow-up
<1 year. Thirty-one studies were included in the systematic
review: 21 observational studies and 10 clinical trials.
Study Characteristics and Results of Individual
Studies
Observational studies reported divergent data on the inci-
dence of MI in the AF population4–24 (Table 1). The first
consolidated evidence suggesting that AF per se is an
independent predictor of MI has been provided by Soliman
et al,9 who analyzed the incidence of MI in a population-based
cohort study that included 1631 participants with and 22 297
without AF from the Reasons for Geographic and Racial
Differences in Stroke (REGARDS) study. The study
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demonstrated that AF increases the risk of MI by 2-fold during
a median follow-up of 4.5 years.
Further support to this finding was provided by other
reports indicating that the annual rate of MI in AF patients is
close to or over 1%/year, with the exception of the Xantus
study where MI incidence was 0.4%.22 Thus, as reported in
Table 1, the annual rate of MI in observational studies of AF
patients ranges from 0.4% to 2.5%.
Higher rates of MI were found in AF patients with stable
coronary artery disease,20 peripheral vascular disease,8 heart
failure,10 or in those undergoing coronary artery interven-
tion15 (Table 1).
A lower annual rate has been described in patients from
Eastern countries. For example, in the J-TRACE study, which
included 2056 Japanese AF patients, the rate of MI was 0.2%/
year.7 Similarly, a large nationwide cohort on 12 114 subjects
from Taiwan found a rate of MI of 0.29%/year.11
Clinical trials reported a lower annual rate of MI in AF26–36
(Table 2). Overall, 46 923 AF patients were treated with
NOACs, 34 800 with VKAs, and 14 725 with antiplatelets. In
particular, MI incidence in AF patients treated with NOACs
ranged from 0.53%/year for apixaban to 1.1%/year for
ximelagatran, which was similar to that in patients treated
with VKAs (from 0.44%/year in the SIFA study to 1.1%/year of
ROCKET trial). Finally, for the group of patients treated with
antiplatelets, the rate of MI ranged from 0.43%/year in the
SIFA study to 1.3%/year in the CHARISMA (Table 2).
The reason for these differences is unclear. Differences in
the populations and the distribution of atherosclerotic risk
factors and comorbidities are possible explanations for some of
these differences. Moreover, another aspect to be considered
is that patients included in clinical trials may have been
monitored more closely than patients in observational studies,
resulting in an improved treatment of comorbid conditions and
atherosclerotic risk factors, and, thereby, in lower rates of MI.
Finally, many patients included in the observational
cohorts were not treated with oral anticoagulants, suggesting
that in the real world of AF, a significant proportion of patients
Figure 1. Flow diagram of search strategy. AF indicates atrial fibrillation; MI, myocardial infarction; RCTs, randomized controlled trials.
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do not receive an adequate prevention for thromboembolism.
This is in keeping with findings from recent surveys reporting
that at least 15% to 30% of AF patients are treated only with
aspirin, or do not receive any antithrombotic treatment.37,38 MI
rate is also influenced by sex, with females being at higher risk
of MI compared to men, as shown in the REGARDS study.9 Of
note, the percentage of females included in the interventional
trials is typically lower than that in the observational studies
(30–40% versus about 50%; Tables 1 and 2).
Synthesis of Results
The annual rate of MI in observational studies including AF
patients ranges from 0.4% to 2.5%. Higher rates of MI were
reported in AF patients with stable coronary artery disease
(11.5%/year), vascular disease (4.47%/year), heart failure
(2.9%/year), or in those undergoing coronary artery interven-
tion (6.3%/year). A low annual rate has been described in AF
patients from Eastern countries (0.2–0.3%/year). Overall, a
lower rate has been described in clinical trials (from 0.4% to
1.3%/year).
Discussion
Mechanisms of Cardiovascular Disease in AF
AF is associated with systemic signs of inflammation that
could promote a pro-thrombotic state and eventually MI.39
Systemic inflammation may depend on AF per se or on the
concomitant presence of the classic atherosclerotic risk
factors, which are typically associated with AF.40 In this
context, it is worth noting that hypertension, diabetes, and
dyslipidemia are associated with platelet activation,41 a key
step in the pathogenesis of MI. This has been evidenced by
studies showing that aspirin, which irreversibly acetylates
COX1, thus inhibiting the formation of the pro-aggregating
molecule thromboxane (Tx) A2,
42 significantly reduces the risk
of cardiovascular outcomes in patients at risk of or with MI.43
Several biomarkers of platelet activation such as plasma
levels of P-selectin, b-thromboglobulin, and soluble CD40L
(sCD40L)44 have been found to be elevated in AF, suggesting
a role for platelets in precipitating vascular disease. This
hypothesis is supported by an observational prospective study
performed in 231 patients with AF, where high plasma levels
of sCD40L discriminated patients who experienced MI during
a follow-up of 28 months.45 Further support to the role of
platelets in favoring MACE is provided by a prospective single-
center study in which the predictive value of 11-dehydro-TxB2,
a marker of in vivo platelet activation, was examined in 837
AF patients followed up to 30 months. During the follow-up,
99 patients experienced fatal and nonfatal MACE. Patients
who were in the top tertile of 11-dehydro-TxB2 showed theT
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highest risk of experiencing ischemic events, including cardiac
complications. The relationship between platelet activation
and cardiovascular disease has been also confirmed by
another prospective observational study in which the predic-
tive value of prostaglandin PGF2alpha was analyzed in 1002
AF patients on treatment with VKAs and followed up for
25.7 months.46 Prostaglandin PGF2alpha is a chemically stable
eicosanoid stemming from arachidonic acid oxidation by
superoxide anion, which activates platelets via TxA2 recep-
tors.47 During the follow-up, 125 patients experienced a MACE
Table 2. Incidence of Myocardial Infarction in Clinical Trials Including Patients With Atrial Fibrillation
Author/Study
Antithrombotic
Agent
Participants
(n)
Female
(%) Age, y
CHADS2/CHA2DS2-VASc
Scores
Number of
MI (n/%)
Follow-Up
(y) Rate of MI (%/y)
SIFA (1997)26 Indobufen 462 54.5 72.8 Not reported 2 (0.43) 1.0 0.43
Warfarin 454 51.5 72.2 68% with ≥2 risk factors 2 (0.44) 0.44
SPORTIF III
(2003)27
Ximelagatran 1704 32.0 70.3 70% with ≥2 risk factors 24 1.4 1.10
Warfarin 1703 30.0 70.1 68% with ≥2 risk factors 13 0.60
ACTIVE W
(2006)28
Clopidogrel+aspirin 3335 33.0 70.2 CHADS2=2.0 36 (1.1) 1.28 0.86
Warfarin 3371 34.0 23 (0.7) 0.55
CHARISMA
(2008)29
Clopidogrel+aspirin 298 19.0 70.0 Not reported 9 (3.0) 2.3 1.30
Aspirin 285 24.0 6 (2.1) 0.91
ACTIVE
(2009)30
Clopidogrel+aspirin 3772 41.4 70.9 CHADS2=2.0 90 (2.4) 3.6 median 0.70
Aspirin 3782 42.4 71.1 115 (3.0) 0.90
RE-LY
(2009)31
Dabigatran 150 mg 6076 36.8 71.5 CHADS2 0 to 1=32.2%;
CHADS2 2=35.2%;
CHADS2 >2=32.6%
89 (1.5) 2.0 0.74
Dabigatran 110 mg 6015 35.7 CHADS2 0 to 1=32.6%;
CHADS2 2=34.7%;
CHADS2 >2=32.7%
86 (1.4) 0.72
Warfarin 6022 36.7 CHADS2 0 to 1=30.9%;
CHADS2 2=37.0%;
CHADS2 >2=32.1%
63 (1.0) 0.53
ARISTOTLE
(2011)32
Apixaban 9120 35.5 70.0 CHADS2=2.1 90 (1.0) 1.8 0.53
Warfarin 9081 35.0 102 (1.1) 0.61
AVERROES
(2011)33
Apixaban 2808 41.0 70.0 CHADS2=2.0 24 1.1 0.80
Aspirin 2791 42.0 70.0 CHADS2=2.1 28 0.90
ROCKET AF
(2011)34
Rivaroxaban 7131 39.7 73.0 CHADS2=3.48 101 (1.4) 1.9 0.90 (overall)
(0.57 AF without
prior MI; 2.77 AF
with prior MI)36
Warfarin 7133 39.7 CHADS2=3.46 126 (1.8) 1.10 (overall) (0.77
AF without prior
MI; 2.80 AF with
prior MI)36
ENGAGE AF
TIMI 48
(2013)35
Edoxaban 60 mg 7035 37.9 72.0 CHADS2 ≤3=77.1%;
CHADS2 4 to 6=22.9%.
133 (1.9) 2.8 0.70
Edoxaban 30 mg 7034 38.8 CHADS2 ≤3=77.8%;
CHADS2 4 to 6=22.2%
169 (2.4) 0.89
Warfarin 7036 37.5 CHADS2 ≤3=77.4%;
CHADS2 4 to 6=22.6%
141 (2.0) 0.65
ACTIVE indicates Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events; AF, atrial fibrillation; ARISTOTLE, Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation; AVERROES, Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for
Vitamin K Antagonist Treatment; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; ENGAGE AF-TIMI 48, Effective
Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48; MI, myocardial infarction; RE-LY, Randomized Evaluation of Long-Term
Anticoagulation Therapy; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation; SIFA, studio italiano fibrillazione atriale; SPORTIF III, Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation.
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including 44 (35.2%) cardiac complications, such as fatal and
nonfatal MI (n=31) and cardiac revascularization (n=13).
Patients in the highest tertile of prostaglandin PGF2alpha were
at higher risk of experiencing MACE, suggesting again a role for
platelets in precipitating cardiac complications.
In addition to atherosclerosis, MI may occur in AF by other
mechanisms. For example, episodes of AF with high ventric-
ular rates may yield type 2 MI, which is characterized by an
imbalance between demand and blood supply, and is usually
associated with non-ST elevation MI.48 Another possibility is
direct thromboembolization from left atrium into the coronary
arteries.49 In 1776 patients with new-onset MI, Shibata
et al50 showed that 52 were due to coronary embolism and
most of them (n=38, 73%) were observed in patients with AF,
suggesting that AF may cause thromboembolism not only to
the cerebral but also to the coronary circulation.
Together these findings suggest that at least 3 mecha-
nisms may account for MI in AF: (1) atherosclerosis and its
associated inflammatory process, yielding a pro-thrombotic
state; (2) direct coronary thromboembolism from left atrial
appendage; and (3) tachyarrhythmia episodes resulting in
supply–demand mismatch (Figure 2).
Predictors of MI in AF
Instrumental and clinical variables have been investigated as
predictors of MI in AF patients. Ankle-brachial index (ABI) and
brachial flow-mediated dilation (FMD), two markers of systemic
atherosclerosis,51 have been prospectively studied to assess
their predictive value against cardiovascular disease in AF.52,53
ABI is a simple, inexpensive, and noninvasive marker of
peripheral artery disease, which is recommended as a first-
line screening tool to assess the presence of a peripheral
artery disease in asymptomatic adults at moderate risk.54 Low
ABI (ie, <0.90) indicates ≥50% stenosis between the aorta and
the distal leg arteries and is associated with an increased risk
of cardiovascular events.55 Prior studies have reported that
AF patients had a low ABI compared to controls,56 and that an
ABI ≤0.90 is detectable in about 20% of the AF population.57
Low ABI is associated with ischemic events also in AF
patients, as shown by the “Ankle-brachial index Prevalence
Assessment-Collaborative Italian Study” (ARAPACIS) registry,
which followed 2027 AF patients for a median of 35 months.
The study showed that a low ABI ≤0.90 was more prevalent in
patients with, compared to those without, a vascular event
(32.2% versus 20.2%, P<0.05). During follow-up, 176 vascular
events occurred (3.81%/year) and, at multivariate analysis,
low ABI was an independent predictor of MI.53
An impaired FMD has been described in many cardiovas-
cular diseases.58,59 An increased risk of cardiovascular events
seems to be present for a value of FMD <10%, further rising
for a value <5%.60 A meta-analysis by Inaba et al showed how
1% increase of FMD is associated with 13% reduction of risk
of cardiovascular event.61
Figure 2. Mechanisms of thromboembolism and atherothrombosis in atrial fibrillation (AF).
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In a cohort of 514 AF patients, a reduced value of FMD was
detected (median 4.6%), with an increase of cardiovascular
events in patients with FMD below the median value (3.06%
[interquartile range 0.00–6.00] versus 4.67% [interquartile
range 1.58–8.22], P=0.027).62
In addition to ABI and FMD, other atherosclerotic risk
factors have been studied in AF. Metabolic syndrome (MetS)
represents a worldwide challenge, with a widespread preva-
lence that appears to be increasing in parallel with the
prevalence of obesity.63 MetS encloses a cluster of car-
diometabolic alterations including visceral adiposity and
atherogenic dyslipidemia. It is estimated that about 40% of
the population aged 60 years old have MetS in the United
States.64 Subjects with MetS have an excess risk for
subsequent cardiovascular events and death, as confirmed
by a recent meta-analysis including 951 083 patients.65
Moreover, a higher risk to develop AF has been well
recognized in patients with MetS,66 and the prevalence of
MetS in AF ranges from 18.8% to 52.1%.67
In accordance with data from the general population
without AF, the association between MetS and cardiovascular
events was also evident in the AF population. For example, in
a cohort of 1019 AF patients followed for a median of
33.7 months, the prevalence of MetS was 52.1%, conferring
an increased risk of MACE (hazard ratio, 1.663; 95% CI,
1.107–2.499; P=0.014).21
In an attempt to improve cardiovascular risk stratifica-
tion, a new simple score to identify AF patients at higher
risk to experience MACE has been proposed.68 The 2MACE
score (Figure 3) assigning 2 points for Metabolic Syndrome
and Age ≥75, 1 point for MI/revascularization, Congestive
heart failure (ejection fraction ≤40%), thromboembolism
(stroke/transient ischemic attack) was developed and
validated in >2000 AF patients in a multicenter study; a
Figure 3. Holistic antithrombotic approach for the management of AF patients starting oral anticoagulation. AF indicates atrial fibrillation;
CHF, congestive heart failure; EF, ejection fraction; INR, international normalized ratio; MI, myocardial infarction; TIA, transient ischemic attack;
TTR, time in therapeutic range.
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2MACE score ≥3 identified patients at highest risk for
MACE.68
Therapeutic Approach to Cardiovascular Risk in
AF Patients
Management of AF patients at risk or with previous MI is
becoming a hot topic, because of the complexity of
antithrombotic treatment in this setting. MI may precede
AF, and about one quarter of the AF population has a history
of MI; thus, MI is considered a risk factor for AF.69 This likely
explains the reason for the frequent association of oral
anticoagulants with aspirin in the AF population, as evidenced
by the recent trials with NOACs in which 29% to 41% of
patients included have been treated with such a combination.
Alternatively, the addition of aspirin to oral anticoagulants
may depend on the physician’s perception of a high risk of
vascular disease. However, this combination therapy is
associated with a significant increase of bleeding, while the
clinical benefit is dubious.20 The use of aspirin in combination
with oral anticoagulants in patients with or without a history
of MI is a critical issue that should be addressed. Previous
studies consistently demonstrated that warfarin alone lowers
the risk of MI recurrence in patients with previous acute
coronary syndromes.70 In accordance with this hypothesis, a
retrospective analysis of the SPORTIF III trial27 showed that
good-quality anticoagulation treatment had a positive impact
on MACE occurrence. Also, in the warfarin arm of the RE-LY
study including >6000 AF patients, a time in therapeutic
range >65% was associated with lower MI risk versus patients
with time in therapeutic range <65%. This finding was
confirmed in a prospective observational study including
627 AF patients who were followed up for 30 months.71 The
study showed that higher time in therapeutic range (>70%)
was associated with lower risk of MI, reinforcing the concept
that a good quality of anticoagulation treatment is necessary
not only to reduce stroke but also MI. A matter of concern is,
however, that the rate of MACE was still elevated with a rate
>2%/year, suggesting that oral anticoagulants alone are not
enough to lower the risk of MI in AF. In this context, it may be
of potential interest to see whether, differently from warfarin,
a combination of aspirin with NOACS could be clinically
effective. The association between rivaroxaban and aspirin
has been tested for patients with recent acute coronary
syndrome in the ATLAS ACS 2–TIMI 51 study72; 15 526
patients were randomly assigned to twice-daily administration
of either 2.5 or 5.0 mg of rivaroxaban or placebo, in addition
to standard medical therapy including low dose of aspirin.
Rivaroxaban, at both dosages, significantly reduced the rate of
death from cardiovascular causes, MI, or stroke, as compared
with placebo, but increased major bleeding with the twice-
daily 5-mg dose. Furthermore, in the ENGAGE AF-TIMI 48
study,35 about 30% of patients were treated with aspirin in
association with VKAs, edoxaban 60 mg, or edoxaban 30 mg;
a positive effect of low-dose edoxaban in association with
aspirin in reducing the rate of cardiovascular events was
observed.
Due to the complexity of treating AF patients with MI,
much effort should be made to come up with cost-effective
prevention strategies. Scores identifying AF patients at higher
risk, such as the 2MACE score, should be further validated, as
a score ≥3 seems to be particularly useful in identifying AF
patients at risk of cardiac events.68 In this context, it would be
interesting to investigate whether AF patients with 2MACE ≥3
would benefit from the combination of old or new anticoag-
ulants with aspirin. Another treatment option may be
represented by statins, as they have been shown to reduce
the risk of MI in primary and secondary prevention trials.73
Furthermore, statins possess antithrombotic activity including
antiplatelet and anticoagulant properties, which may be useful
in AF patients, who are characterized by a systemic and local
ongoing prothrombotic state. Preliminary data from an
observational study demonstrated that statins reduce cardio-
vascular death in AF patients.74 In the meantime, correction
of atherosclerotic risk factors with a pharmacological
approach, or a dietary intervention, could be a reasonable
strategy to reduce the atherosclerotic complications. AF
patients, for instance, could be advised to adhere to
Mediterranean diet, which is known to possess antioxidant
property, does not interfere with time in therapeutic range in
warfarin-treated patients,75 and is associated with lower risk
of MI and stroke.76
Based on these considerations, a holistic approach includ-
ing management of thromboembolism and MI is proposed
(Figure 3). Thus, in addition to the CHA2DS2-VASc and HAS-
BLED scores to stratify stroke and bleeding risk, respectively,
inclusion of a score for MACE risk should be taken into
account. This approach could prove useful not only to assess
the stroke and bleeding risks, but also to assess the MACE
risk, and to drive therapeutic choices. For instance, future
clinical trials are needed to examine the usefulness of addition
of aspirin or statins to oral anticoagulants in reducing the risk
of both MI and stroke in AF patients.
Limitation
A limitation of this systematic review may be represented by
the different definitions used to diagnose MI, as these
changed over time, and may be responsible for some of the
differences in the annual rate of MI observed among studies.
In particular, since the first universal definition of MI,77 which
indicated cardiac troponin over creatine kinase as a more
specific diagnostic biomarker for MI, the inclusion of electro-
cardiographic changes other than ST-segment modifications
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or Q waves (ie, new-onset left bundle branch block), and
availability of new cardiac imaging techniques have improved
the diagnosis of MI.78
Conclusions
In conclusion, MI and AF are closely related; MI may precede or
complicate the clinical course of AF. The presence of MI in AF
patients creates a challenge in clinical management, because of
the complexity of using anticoagulants and antiplatelet drugs,
with the ensuing high risk of bleeding. Reducing the risk of MI in
AF should be an objective for future studies.
Disclosures
None.
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